Get the Stockscreener App
63.99
0.05%
-0.03
Hologic Inc stock is traded at $63.99, with a volume of 1.58M.
It is down -0.05% in the last 24 hours and up +0.03% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$64.02
Open:
$64.58
24h Volume:
1.58M
Relative Volume:
0.49
Market Cap:
$14.26B
Revenue:
$4.03B
Net Income/Loss:
$556.70M
P/E Ratio:
27.00
EPS:
2.37
Net Cash Flow:
$970.10M
1W Performance:
-2.63%
1M Performance:
+0.03%
6M Performance:
-8.23%
1Y Performance:
-17.60%
1-Day Range:
$63.61
$64.64
1-Week Range:
$63.22
$65.81
52-Week Range:
$51.90
$84.67
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
63.99 | 14.65B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
518.62 | 183.53B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
178.85 | 50.43B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.35 | 43.27B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
257.92 | 37.30B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
210.89 | 16.32B | 2.90B | 467.20M | 306.90M | 6.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Hologic Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia
What analysts say about Hologic Inc. stockExplosive market performance - PrintWeekIndia
What drives Hologic Inc. stock pricePhenomenal investment performance - Autocar Professional
Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount? - simplywall.st
Is Hologic Inc. a good long term investmentExplosive trading growth - Jammu Links News
Unexpected Trends Reshaping the Uterine Fibroid (UF) Treatment - openPR.com
Sentinel Node Biopsy Market Future Business Opportunities - openPR.com
Hologic Refinances Loan to Enhance Financial Flexibility - TipRanks
Hologic’s SWOT analysis: breast health recovery boosts stock outlook - Investing.com
What to Expect From Hologic's Q3 2025 Earnings Report - MSN
Cervical Dysplasia Market is Booming Worldwide |Hologic,Qiagen,Advaxis - openPR.com
Mizuho Raises Hologic Price Target to $70, Maintains Outperform Rating - AInvest
Hologic, Inc. (HOLX) Stock Forecasts - Yahoo Finance
Hologic (HOLX) Maintains Outperform Rating, Price Target Raised by Mizuho | HOLX Stock News - GuruFocus
Hologic Rides on AI-Powered Breast Health Innovations: What's Next? - Nasdaq
How the Computer Aided Detection Market Will Evolve by 2032 - openPR.com
Why Hologic (HOLX) Dipped More Than Broader Market Today - Yahoo Finance
Hologic, Inc. Fiscal Q3 2025 Earnings Release and ProjectionsNews and Statistics - IndexBox
Hologic's Q3 2025 Earnings: A Hidden Gem in Medtech Undervaluation - AInvest
Hologic Q3 2025 Earnings Report: Analyst Expectations and Stock Performance - AInvest
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
What makes Hologic Inc. stock price move sharplyDaily Top Gainers - beatles.ru
Hologic Maintains Strength in Diagnostics but Cuts to Medicaid Could Pressure Volume - Morningstar
Global Uterine Fibroids Treatment Devices Market to grow at - openPR.com
Hips & Knees Reconstructive Market Attracts 3D Implant - openPR.com
Hologic's GYN Surgical Dominance: What's Powering The Road Ahead? - Barchart.com
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead? - The Globe and Mail
Hologic (HOLX) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Citi upgrades Hologic stock rating to Buy on valuation and growth outlook - Investing.com Nigeria
Citigroup Upgrades Hologic (HOLX) with Revised Price Target | HO - GuruFocus
Citi upgrades Hologic stock rating to Buy on valuation and growth outlook By Investing.com - Investing.com South Africa
Hologic (HOLX) Upgraded by Citi with Increased Price Target | HOLX Stock News - GuruFocus
Citigroup Upgrades Hologic to Buy From Neutral, Adjusts Price Target to $80 From $60 - MarketScreener
Hologic (HOLX) Price Target Raised by Evercore ISI Group | HOLX Stock News - GuruFocus
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap? - Nasdaq
The Price Is Right For Hologic, Inc. (NASDAQ:HOLX) - 富途牛牛
BioZorb Lawsuit LawyerBreast Biopsy Marker RecallJuly 2025 Update - Levin Papantonio
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - MSN
BioZorb Lawsuit and Settlement Information: July 2025 - AboutLawsuits.com
Hologic to Announce Financial Results for the Third Quarter of F - GuruFocus
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025 - MarketScreener
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern - Yahoo
Hologic, Inc.(NasdaqGS: HOLX) dropped from Russell 1000 Dynamic Index - MarketScreener
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value - Zacks Investment Research
Is Hologic, Inc. (NASDAQ:HOLX) Undervalued Despite Strong Growth Prospects? - AInvest
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):